Welcome, Guest. Please login or register.
July 18, 2024, 05:44:35 pm

Login with username, password and session length

  • Total Posts: 55130
  • Total Topics: 4851
  • Online Today: 203
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 68
Total: 68


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: As Hep B Treatment, Viread Tied to Lower Liver Cancer Risk Than Baraclude  (Read 6536 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
Treating chronic hepatitis B virus (HBV) with Viread (tenofovir disoproxil fumarate, or TDF) is associated with a lower risk of hepatocellular carcinoma (HCC, the most common form of liver cancer) compared with using Baraclude (entecavir), Medscape reports.

Publishing their findings in JAMA Oncology researchers analyzed data from a nationwide population cohort study of South Koreans with chronic hep B who started treatment for the virus for the first time with Baraclude (11,464 people) or Viread (12,692 people) between January 2012 and December 2014. The data came from the Korean National Health Insurance Service database.



© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.